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The UDP Glucuronosyl Transferase (UGT) enzymes are important in the pharmacokinet-
ics, and conjugation, of a variety of drugs including non-steroidal anti-inflammatory drugs
(NSAIDs) as well as anabolic androgenic steroids (AAS). Testosterone glucuronidation
capacity is strongly associated with a deletion polymorphism in the UGT2B17 gene. As
the use of high doses of NSAIDs has been observed in athletes there is a risk for a drug–
drug interaction that may influence the doping tests for AAS. In vitro studies show inhibitory
potential on UGT2B7, 2B15, and 2B17 enzymes by NSAIDs. The aim of this study was to
investigate if concomitant use of NSAIDs and a single dose of testosterone enanthate
would affect the excretion rate of testosterone and epitestosterone glucuronide (TG and
EG) as well as theT/E ratio, thereby affecting the outcome of the testosterone doping test.
The study was designed as an open, randomized, cross-over study with subjects being
their own control.The 23 male healthy volunteers, with either two, one or no allele (ins/ins,
ins/del, or del/del) of the UGT2B17 gene, received the maximum recommended dose of
NSAID (Ibuprofen or Diclofenac) for 6 days. On day three, 500 mg of testosterone enanthate
was administered. Spot urine samples were collected for 17 days. After a wash-out period of
4 months the volunteers received 500 mg testosterone enanthate only, with subsequent
spot urine collection for 14 days. The glucuronides of testosterone and epitestosterone
were quantified. NSAIDs did not affect the excretion ofTG or EG before the administration
of testosterone. The concomitant use of NSAIDs and testosterone slightly increased the
TG excretion while the EG excretion was less suppressed compared to testosterone use
only. The effects of the NSAIDs on the TG and EG excretion did not differ between the
UGT2B17 genotype groups. In conclusion, the outcome of testosterone doping tests does
not seem to be affected by the use of NSAIDs.
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INTRODUCTION
Testosterone is one of the most commonly abused anabolic andro-
genic steroids (AAS) within doping in sports and for enhancement
of physical performance (Handelsman and Heather, 2008). Testos-
terone and other anabolic compounds are prohibited in sports
by the World Anti-Doping Agency (WADA). In 2011 anabolic
agents represented the most frequently reported adverse analyt-
ical findings and atypical findings (59.4%) by accredited doping
laboratories. Among these, elevated testosterone/epitestosterone
ratios represented 60.0% of the findings, although only 10% of
these were adverse analytical findings (WADA, 2011).
To discriminate exogenous testosterone from testosterone of
endogenous origin the urinary ratio of testosterone glucuronide
(TG) to epitestosterone glucuronide (EG) (T/E ratio) is used
(Donike et al., 1983, 1985). Based on population studies (Donike
et al., 1983, 1985) a normal T/E ratio would be∼1.0 and a T/E ratio
above six was initially considered suspicious of doping. However,
additional knowledge showed that Asian individuals excreted low
amounts of TG, and as a result low T/E ratios increasing the risk
of false negative doping test results (Park et al., 1990; de la Torre
et al., 1997). Due to these findings the T/E ratio was lowered to 4.0
in 2004.
Testosterone is inactivated, and excreted in urine, mainly as
glucuronide conjugates, the formation of which is catalyzed by
UDP-glucuronosyltransferases (UGTs). These enzymes play a key
role in the homeostasis of a number of endogenous molecules
including steroid hormones (Belanger et al., 2003). The UGT
super family is subdivided into UGT1A, UGT2A, and UGT2B
families based on sequence identity (Mackenzie et al., 1997). In
humans UGTs 2B7, 2B15, and 2B17 are the main catalysts of
the glucuronidation of androgens and their metabolites (Belanger
et al., 2003). Testosterone glucuronidation is mainly dependent on
UGT2B17 and to a lesser extent UGT2B15 (Turgeon et al., 2001)
whereas epitestosterone is conjugated by UGT2B7 (Coffman et al.,
1998; Sten et al., 2009a).
The human UGT2B genes are clustered on chromosome 4q13-
21.1 and encode seven functional enzymes: UGT2B4, B7, B10,
B11, B15, B17, and B28 (Guillemette, 2003). In vivo, UGT2B17 has
been identified as the main enzyme in testosterone glucuronida-
tion where a gene deletion in UGT2B17 was associated by us with
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low, or negligible, excretion of testosterone in urine (Jakobsson
et al., 2006). All subjects devoid of UGT2B17 had a T/E ratio
below 0.4. This polymorphism was considerably more common
in a Korean Asian than in a Swedish Caucasian population, with
66.7 and 9.3% deletion/deletion (del/del) homozygotes, respec-
tively (Jakobsson et al., 2006). This correlates to earlier findings of
low T/E in Asians as described above. Further, after testosterone
administration individuals devoid of the UGT2B17 gene rarely
exceed this cut-off ratio (Schulze et al., 2008b). Individuals carry-
ing one (ins/del) or two (ins/ins) copies of this gene clearly passed
the cut-off ratio and some even exceeded the cut-off level prior to
challenge with testosterone.
The UGT enzymes are important in the pharmacokinetics, and
conjugation, of a variety of drugs including non-steroidal anti-
inflammatory drugs (NSAIDs) (Davies, 1998; Kuehl et al., 2005).
NSAIDs are a class of therapeutic agents used in the treatment of
pain and inflammation and are commonly used by athletes. In fact,
according to recent studies, inappropriate use of high doses and
concomitant use of several different NSAIDs has been observed
in athletes (Alaranta et al., 2008; Warden, 2009). Since steroids
and NSAIDs are both inactivated by UGT enzymes there is a risk
for a drug–drug interaction (Kiang et al., 2005). In vitro stud-
ies show inhibitory potential on UGT2B7 (Mano et al., 2007),
2B15 and 2B17 enzymes by NSAIDs (Sten et al., 2009b). In
the latter study both diclofenac and ibuprofen inhibited testos-
terone glucuronidation in liver microsomes, as well as recombi-
nant UGT2B15 and UGT2B17 enzymes. However, epitestosterone
glucuronidation activity in human liver microsomes was largely
insensitive to ibuprofen and diclofenac. To our knowledge this has
not been studied in vivo.
The aim of this study was to investigate in healthy male vol-
unteers whether a concomitant use of NSAIDs (Ibuprofen or
Diclofenac) and a single dose of testosterone enanthate would
affect the excretion rate of TG and EG, and hence the T/E ratio,




The target group was healthy male volunteers aged 18–50 years. A
total number of 33 subjects were genotyped for the UGT2B17
deletion polymorphism to fill the pre-determined number of
approximately 10 subjects in each of the three different geno-
type panels (ins/ins, ins/del and del/del). All subjects originated
from different ethnicities and therefore the genotype frequencies
in this sample are not representative of any particular popula-
tion. In this particular genotyped population group 28% were
homozygous for the gene deletion (del/del), 33% were heterozy-
gous (ins/del), and 39% had two copies of the gene (ins/ins). In
total, eight del/del, seven ins/del, and eight ins/ins participants
completed the study. Study population characteristics are pre-
sented in Table 1. In addition to genotyping,all subjects underwent
a medical examination including laboratory tests before enroll-
ment to exclude the possibility of any disease. No pharmaceutical
compounds other than those in this study were allowed. Further
inclusion-criteria included a negative screening for illegal drugs,
AAS, HIV, and hepatitis B or C virus. For inclusion it was also
Table 1 | Study population characteristics at screening.
UGT2B17
Genotype
Age (years) Height (cm) Weight (kg) BMI (kg/m2)
del/del (n=8) 29.2±4.3 180±6.9 80.6±9.7 24.8±2.7
ins/del (n=7) 31.1±4.7 179±6.1 81.4±9.2 25.4±2.8
ins/ins (n=8) 28.1±5.1 181±5.2 79.6±6.1 24.3±2.3
required that the subject was not a member of any organization
belonging to the Swedish Sports Confederation, had been diag-
nosed and/or treated for a malignancy within the past 5 years or
having a known allergy to the study substances. All participants
gave informed consent consistent with the approval of the Ethics
Review Board at Karolinska Institutet in Stockholm. Two subjects
were excluded prior to the start of the study due to concomitant
medication. The genotyped subjects that did not participate were
dropouts (n= 8). The study (protocol number 2007-002655-16)
was conducted according to the Helsinki declaration and the ICH
Harmonized Tripartite Guideline for Good Clinical Practice.
GENOTYPING OF UGT2B17
The copy number of UGT2B17 was determined in the 23 males
included in the study. The numbers of UGT2B17 genes quantified
with a real-time PCR analysis, using the expression of albumin as
an endogenous control. The genotyping methods are based on the
5′-nuclease activity method (TaqMan®) employing two primers
and two fluorescent labeled probes in a real-time based assay as
earlier described (Schulze et al., 2008a).
DESIGN
The study was designed as an open, randomized, cross-over study
with subjects being their own control (Figure 1). In the Phase I,
starting 3 days before (−3) administration of Testoviron®-Depot,
subjects received either diclofenac (Voltaren®, n= 13) 50 mg× 3
or ibuprofen (Ipren®, n= 10) 400 mg× 3 for six consecutive days
(ending on day-2).
On day-0 all participants from the different genotype panels
were given a single dose of 500 mg testosterone enanthate in rici-
nus oil as a single intramuscular dose of Testoviron® – Depot
(kindly provided by Bayer Schering Pharma) equivalent to 360 mg
testosterone. Before administration of the testosterone, urine sam-
ples were collected during 4 days (days-3, -2, -1, and 0). Samples
of urine were further collected for 14 days, all between 06–10 am.
In the Phase II all participants were given a single dose of 500 mg
testosterone enanthate in ricinus oil as a single intramuscular dose
of Testoviron®-Depot equivalent to 360 mg testosterone. A base-
line urine sample was collected before the injection and further for
14 days after the injection, all between 06:00 and 10:00 a.m. The
wash-out period between the two phases was at least 4 months.
Adverse drug reactions (ADRs) were monitored from inclusion of
each phase until day-14 after administration of testosterone. No
major ADRs were registered. No follow-up was needed.
BLOOD AND URINE SAMPLES
Venous blood was obtained from the cubital vein and collected in
EDTA tubes for DNA extraction. The urine samples were collected
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FIGURE 1 | Illustration of the open, randomized, cross-over study with subjects being their own control. The wash-out period was at least 4 months.




Testosterone (ng/µmol cr) Epitestosterone (ng/µmol cr) T/E ratio
Day-3** Day-0** Day-3 Day-0 Day-3** Day-0**
del/del (n=8) 0.33±0.34 0.38±0.24 5.2±2.4 5.2±1.9 0.07±0.06 0.08±0.05
ins/del (n=7) 6.1±2.0 4.4±1.9 6.3±3.2 5.8±4.0 1.2±0.70 0.90±0.39









del/del (n=8) 0.46±0.33 4.5±3.9 0.15±0.11
ins/del (n=7) 4.0±1.1 5.0±2.2 0.94±0.60
ins/ins (n=8) 8.7±5.6 4.2±2.6 2.1±0.77
The values are given as the mean± standard deviation. Asterisks denote a statistically significant difference (*p<0.001; **p<0.0001) between the genotype as
determined by ANOVA.
and kept refrigerated for maximum 48 h and then frozen at−20˚C.
All samples were collected between 06:00 and 10:00 a.m.
URINE ANALYSES
Urinary unconjugated steroids and steroid glucuronides were
determined using liquid chromatography-mass spectrometry
(LC/MS) as described previously (Schulze et al., 2011). The
method was modified to only quantify the glucuronides of testos-
terone and epitestosterone. The day-to-day variation of the instru-
ment was minimized using the mixture of authentic standards
analyzed with every batch of samples.
DATA ANALYSES
Integration, calibration, and data evaluation was performed by the
TargetLynx software (Waters Associates, Manchester, UK).
The between-subject variation in urine dilution was corrected
for by dividing the concentration values by the urinary creatinine
(cr) concentration, which was determined by colorimetric analysis
(DRI Creatinine-Detect Test; Thermo Fisher Scientific, Waltham,
MA, USA). Statistical analyses for comparison of hormonal lev-
els of TG, EG, and T/E were performed with Student’s two-tailed
t test or Mann–Whitney U test according to distribution of the
data. When comparing three groups; ANOVA with Tukey’s post hoc
test or Kruskal–Wallis with Dunn’s post hoc test according to
distribution. p< 0.05 regarded as significant.
RESULTS
BASELINE URINARY STEROIDS
The average baseline urinary glucuronidated testosterone (TG)
and epitestosterone (EG) concentrations and T/E ratios for
Phase I before and after 3 days of NSAID administration are
presented in Table 2. Neither the TG levels, EG levels nor
the T/E ratio were affected by NSAID administration. For the
ins/del group the TG levels decreased slightly after 3 days of
NSAID administration, however, this decrease was not statis-
tically significant (p= 0.13). As expected, the TG levels and
T/E ratio differed significantly between the del/del group and
the other two genotype groups. There was no difference
in the EG levels. No difference in baseline values between
individuals aimed for receiving ibuprofen or diclofenac was
observed.
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FIGURE 2 | Average urinary testosterone/epitestosterone ratios (A) and
urinary testosterone glucuronide excretion (ng/µmol creatinine) (B)
during 14days in UGT2B17 del/del (top), ins/del (middle) and ins/ins
(bottom) genotype groups of healthy volunteer males. The subjects were
followed during two administration cycles with at least 4 months wash-out
between the cycles. During one cycle NSAID was administered for 6 days
(day-3 to day-2). In both cycles an intramuscular dose of 500 mg testosterone
enanthate was administered on day-0. Asterisks denote statistically
significant differences between the groups (*p<0.05; **p<0.01). Vertical
bars denote standard deviations.
The average baseline T/E ratios for Phase II are presented in
Table 2. Similar to Phase I the TG levels and the T/E ratio differed
significantly between the genotype groups.
URINARY STEROID PROFILE AFTER TESTOSTERONE ADMINISTRATION
The T/E ratios in Phase I (NSAID+T) and Phase II (T only) for
the different genotype panels after testosterone dose are shown
in Figure 2A. There were no statistically significant differences
between Phase I and Phase II. In the del/del group there was one
individual with EG levels decreasing much less in Phase I com-
pared to Phase II, while his TG levels were similar in both Phase I
and Phase II. This individual is shown as a dotted line in Figure 2A
(top).
The TG increased slightly more in Phase I (NSAID+T) com-
pared to Phase II (T only) after dose in all genotype groups
(Figure 2B). However the increase was only significant in the
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ins/del genotype group on day-1 (p= 0.02) and day-2 (p= 0.05).
Taken all genotype groups together the maximum increase in TG
excretion compared to baseline was about 80% higher in Phase I
(NSAID+T) compared to Phase II (T only). There was no statisti-
cally significant difference between the diclofenac group compared
to the ibuprofen group.
The excretion of EG decreased steadily to low levels after
the testosterone dose as expected. The decrease was, however,
more pronounced in Phase II (T only) compared to Phase I
(NSAID+T) in all genotype groups the first 5 days after the
testosterone dose. This corresponds to the time the study sub-
jects still had relatively high concentrations of NSAID in their
circulation. As the EG excretion is not dependent on UGT2B17
genotype the three UGT2B17 genotype panels were grouped
for increased statistical power (Figure 3). On days 1–5 after
the testosterone dose, the EG concentrations were significantly
less suppressed in Phase I (+NSAID) compared to Phase II
(p= 0.04− 0.003) with the exception of day-2 (p= 0.08). No
difference was seen between the diclofenac and the ibuprofen
group.
Taken together the results indicate that NSAID slightly induces
TG and decreases suppression of EG excretion, hence there will be
no effect on the T/E ratio.
DISCUSSION
In this study, for the first time, we aimed to study if NSAIDs
affect testosterone glucuronidation, epitestosterone glucuronida-
tion and hence T/E ratios in vivo. Based on previous in vitro data
(Sten et al., 2009b) the hypothesis was that NSAIDs would interact
with the glucuronidation of testosterone but not epitestosterone
leading to lower TG excretion and lower T/E ratios. However,
the opposite was seen, with a minor increase in TG and less
suppression of EG excretion leading to unchanged T/E ratios.
In our in vitro study (Sten et al., 2009b) the IC50 values for
the inhibition of testosterone glucuronidation by ibuprofen was
213 (95% CI; 129–354) µM and by diclofenac 64 (95% CI;53–
80) in human liver microsomes (Sten et al., 2009b). Therapeutic
plasma concentrations for ibuprofen are 73–146µM, which are
in the same range as the IC50 value. For diclofenac the therapeu-
tic plasma concentrations are considerably lower (about 5µM)
than the in vitro IC50 value. We still decided to include diclofenac
in the in vivo study, as this is a very common NSAID used by
athletes.
It is not straight forward to predict inhibitory interactions
involving glucuronidated drugs from in vitro data (Miners et al.,
2006) and references therein. We have shown that testosterone glu-
curonidation rate in vitro in liver microsomes was only twofold
higher in livers with one or two copies of the UGT2B17 gene com-
pared to UGT2B17 del/del livers (Jakobsson et al., 2006). In vivo,
urinary levels of TG in UGT2B17 ins/ins and ins/del individuals
are over 10 times higher than TG levels in UGT2B17 del/del indi-
viduals (this study; Jakobsson et al., 2006; Schulze et al., 2008b).
In addition, in our in vitro experiment only liver microsomes and
recombinant enzymes were studied (Sten et al., 2009b), while the
UGT2B enzymes are highly expressed in several different tissues
(Nakamura et al., 2008).
Our intention with this study was aimed at mimicking a situ-
ation that doping laboratories may face when athletes are taking
NSAIDs. We conclude that NSAIDs, even in large doses, will not
have any significant effect on testosterone doping tests results,
FIGURE 3 | Average urinary epitestosterone glucuronide excretion
(ng/µmol creatinine) during 14days in healthy volunteer males. The
subjects were followed during two administration cycles with at least
4 months wash-out between the cycles. During one cycle NSAID was
administered for 6 days (day-3 to day-2). In both cycles an intramuscular dose
of 500 mg testosterone enanthate was administered on day-0. Asterisks
denote statistically significant differences between the groups (*p<0.05;
**p<0.01) Vertical bars denote standard deviations.
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at least not with injected testosterone esters. Oral formulations
of testosterone are metabolized in the liver to a much higher
extent than injectable testosterone esters. It would be interesting
to investigate if oral formulations of testosterone together with
NSAID would show different results. It is possible that this setting
would be more similar to our in vitro investigation where liver
microsomes were used (Sten et al., 2009b).
To our knowledge the interaction of NSAID with the glu-
curonidation enzymes has not been extensively studied in vivo.
Van der Logt et al. (2004) demonstrated increased UGT enzyme
activities in rats treated with ibuprofen in intestine but not in
liver.
The plasma concentrations of ibuprofen and diclofenac are
known to be highly dependent on polymorphisms in CYP2C9 and
CYP2C8 (Garcia-Martin et al., 2004; Zhou et al., 2010). Indeed,
the TG excretion increased more than 20% in 16 study subjects,
was unchanged in six and was decreased in one subject after the
testosterone injection with concomitant use of NSAID compared
to a testosterone injection only.
We chose to use a large dose of testosterone enanthate in order
to have plasma concentrations as close as possible to our previous
in vitro investigation (Sten et al., 2009b), and also, since our study
group was quite small, to be able to detect any changes in TG and
EG excretion. It would be interesting to use different formulations
of testosterone rather than different types of NSAIDs.
Several in vitro studies have shown UGT2B inhibition with dif-
ferent types of food or drink (Jenkinson et al., 2012a,b) or drugs
(Sten et al., 2009b) and speculated that this will affect the testos-
terone excretion and testosterone doping tests. Our in vivo study
does not confirm previous in vitro results, rather the opposite, and
this should be taken into consideration when extrapolating in vitro
results to the in vivo situation.
In conclusion, the concomitant use of NSAIDs and testosterone
esters slightly increases the TG excretion while the EG excretion
is less suppressed compared to testosterone use only. The T/E
ratios are not affected by NSAID intake either before or after the
testosterone administration.
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